Protagonist Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on May 8, 2019, by Protagonist Therapeutics, Inc., a Delaware corporation and emerging growth company. The filing reports financial results for the quarter ended March 31, 2019. The company's common stock trades on The Nasdaq Stock Market under the symbol PTGX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that the company has reported its first-quarter 2019 results and incorporates the full details by reference to an attached press release (Exhibit 99.1).
Material Changes
No material changes versus the prior comparable period are detailed within the text of this 8-K filing. The filing indicates that the company has released its Q1 2019 results but does not summarize the specific variances or trends in this document.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It references a press release titled "Protagonist Therapeutics Reports First Quarter 2019 Financial Results" for these details. The filing includes a standard disclaimer stating that the information is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific Q1 2019 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the referenced press release.
- Confirm the status of the company's emerging growth company election and its implications for financial reporting.